Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes
Tóm tắt
Từ khóa
Tài liệu tham khảo
Allgot, 2003, Diabetes Atlas, 360
Klein, 1995, Hyperglycemia and microvascular and macrovascular disease in diabetes, Diabetes Care, 18, 258, 10.2337/diacare.18.2.258
Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405
DeFronzo, 1997, Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes, Diabetes Rev, 5, 177
Kahn, 2003, The relative contribution of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes, Diabetologia, 46, 3, 10.1007/s00125-002-1009-0
Matthews, 1985, Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883
Ferannini, 1998, How to measure insulin sensitivity, J Hypertens, 16, 895, 10.1097/00004872-199816070-00001
Reaven, 1995, Pathophysiology of insulin resistance in human disease, Physiol Rev, 75, 473, 10.1152/physrev.1995.75.3.473
Yki-Jarvinen, 2003, Textbook of Diabetes, 22.1
Krentz, 2002, Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents?, Br J Diabetes Vasc Dis, 2, 370, 10.1177/14746514020020050501
Grundy, 2004, Definition of metabolic syndrome, Circulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6
Ginsberg, 2000, Insulin resistance and cardiovascular disease, J Clin Invest, 106, 453, 10.1172/JCI10762
Grundy, 1999, Diabetes and cardiovascular disease, Circulation, 100, 1134, 10.1161/01.CIR.100.10.1134
Bailey, 1999, Insulin resistance and antidiabetic drugs, Biochem Pharmacol, 58, 1511, 10.1016/S0006-2952(99)00191-4
Saltiel, 2001, Insulin signaling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a
Zierath, 2000, Insulin action and insulin resistance in human skeletal muscle, Diabetologia, 43, 821, 10.1007/s001250051457
Inzucchi, 2002, Oral antihyperglycemic therapy for type 2 diabetes, JAMA, 287, 360, 10.1001/jama.287.3.360
Bailey, 2003, Antidiabetic drugs, Br J Cardiol, 10, 128
Bailey, 1989, Traditional plant medicines as treatments for diabetes, Diabetes Care, 12, 553, 10.2337/diacare.12.8.553
Wiernsperger, 1999, The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms, Drugs, 58, 31, 10.2165/00003495-199958001-00009
Wiernsperger, 1996, Preclinical pharmacology of biguanides, Handbook Exp Pharmacol, 119, 305, 10.1007/978-3-662-09127-2_12
Musi, 2002, Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes, Diabetes, 51, 2074, 10.2337/diabetes.51.7.2074
Owen, 2000, Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain, Biochem J, 348, 607, 10.1042/bj3480607
UK Prospective Diabetes Study (UKPDS) Group, 1998, Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8
Bailey, 2002, United Kingdom Prospective Diabetes Study: implications for metformin, Br J Cardiol, 9, 115
Wiernsperger, 2000, Metformin: intrinsic vasculoprotective properties, Diabetes Technol Therap, 2, 259, 10.1089/15209150050025230
Cusi, 1998, Metformin: a review of its metabolic effects, Diabetes Rev, 6, 89
Grant, 2003, Beneficial effects of metformin on haemostasis and vascular function in man, Diabetes Metab, 29, S44, 10.1016/S1262-3636(03)72787-6
Howlett, 1999, A risk-benefit assessment of metformin in type 2 diabetes mellitus, Drug Safety, 20, 489, 10.2165/00002018-199920060-00003
Morin-Papunen, 2003, Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 4649, 10.1210/jc.2002-021688
Abbasi, 2004, Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus, Metabolism, 53, 159, 10.1016/j.metabol.2003.07.020
Stumvoll, 2002, Glitazones: clinical effects and molecular mechanisms, Ann Med, 34, 217, 10.1080/713782132
Lebovitz, 2001, Rosiglitazone monotherapy is effective in patients with type 2 diabetes, J Clin Endocrinol Metab, 86, 280, 10.1210/jcem.86.1.7157
Phillips, 2001, Once- and twice-daily dosing with rosiglitazone improves glycaemic control in patients with type 2 diabetes, Diabetes Care, 24, 308, 10.2337/diacare.24.2.308
Wyne, 2004, The effects of rosiglitazone in poorly controlled, drug-naive patients with type 2 diabetes mellitus, Diabetes, 53
Bell, 2003, B-cell rejuvenation with thiazolidinediones, Am J Med, 115, 20S, 10.1016/j.amjmed.2003.08.010
Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, 20, 649
Murphy, 2000, PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer, Trends Pharmacol Sci, 21, 469, 10.1016/S0165-6147(00)01559-5
Miyazaki, 2001, Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II patients, Diabetologia, 44, 2210, 10.1007/s001250100031
Berger, 2002, The mechanisms of action of PPARs, Annu Rev Med, 53, 409, 10.1146/annurev.med.53.082901.104018
Furnsinn, 2002, Thiazolidinediones: metabolic actions in vitro, Diabetologia, 45, 1211, 10.1007/s00125-002-0899-1
Haffner, 2002, Effect of rosiglitazone on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, 106, 679, 10.1161/01.CIR.0000025403.20953.23
Barbier, 2002, Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis, Arterioscler Thromb Vasc Biol, 22, 717, 10.1161/01.ATV.0000015598.86369.04
Lebovitz, 2001, Insulin resistance and its treatment by thiazolidinediones, Recent Prog Horm Res, 56, 265, 10.1210/rp.56.1.265
Maeda, 2001, PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein, Diabetes, 50, 2094, 10.2337/diabetes.50.9.2094
Roberts, 2003, Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions, Curr Opin Lipidol, 14, 567, 10.1097/00041433-200312000-00004
Freed, 2002, Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities of type 2 diabetes mellitus, Am J Cardiol, 90, 947, 10.1016/S0002-9149(02)02659-0
Cheng-Lai, 2000, Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes, Heart Dis, 2, 326
Carey, 2002, Effects of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients, Obesity Res, 10, 1008, 10.1038/oby.2002.137
St John Sutton, 2002, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with type 2 diabetes, Diabetes Care, 25, 2058, 10.2337/diacare.25.11.2058
Bennett, 2004, Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance, Diabetic Med, 21, 415, 10.1111/j.1464-5491.2004.01155.x
Bakris, 2003, Rosiglitazone reduces urinary albumin excretion in type II diabetes, J Hum Hypertens, 17, 7, 10.1038/sj.jhh.1001444
Sidhu, 2003, The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients, J Am Coll Cardiol, 42, 1757, 10.1016/j.jacc.2003.04.001
Pistrosch, 2004, In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control, Diabetes Care, 27, 484, 10.2337/diacare.27.2.484
Shargorodsky, 2003, Treatment with rosiglitazone reduces hyperinsulinaemia and improves arterial elasticity in patients with type 2 diabetes mellitus, Am J Hypertens, 16, 617, 10.1016/S0895-7061(03)00911-7
Choi, 2003, Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes, Diabetes, 52, A19
Fonseca, 2000, Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial, JAMA, 283, 1695, 10.1001/jama.283.13.1695
Jones, 2003, Addition of rosiglitazone to metformin is most effective in obese insulin- resistant patients with type 2 diabetes, Diabetes Obes Metab, 5, 163, 10.1046/j.1463-1326.2003.00258.x
Rosenstock, 2004, Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients, Diabetes, 53
Emslie-Smith, 2003, The problem of polypharmacy in type 2 diabetes, Br J Diabetes Vasc Dis, 3, 54, 10.1177/14746514030030010901
Avandamet Prescribing Information GlaxoSmithKline, Durham, North Carolina, February 2004
Baldwin, 1999, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone, Br J Clin Pharmacol, 48, 424, 10.1046/j.1365-2125.1999.00030.x
Niemi, 2003, Gemfibrozil considerably increases the plasma concentrations of rosiglitazone, Diabetologia, 46, 1319, 10.1007/s00125-003-1181-x
Scheen, 1996, Clinical pharmacokinetics of metformin, Clin Pharmacokinet, 30, 359, 10.2165/00003088-199630050-00003
Lebovitz, 2002, Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction, Diabetes Care, 25, 815, 10.2337/diacare.25.5.815
Harborne, 2003, Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome, Lancet, 361, 1894, 10.1016/S0140-6736(03)13493-9
Gallagher, 2004, A retrospective study of patients with type 2 diabetes treated with triple therapy (metformin, a sulphonylurea and a thiazolidinedione), Diabetic Med, 21, 65
Thomas, 2004, Triple therapy in type 2 diabetes mellitus, Diabetic Med, 21, 63
Marchesini, 2001, Metformin and non-alcoholic steatohepatitis, Lancet, 358, 893, 10.1016/S0140-6736(01)06042-1
Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone, Hepatology, 38, 1008, 10.1053/jhep.2003.50420
Behagavathula, 2004, Rosiglitazone inhibits proliferation, motility and matrix metalloproteinase production in keratinocytes, J Invest Dermatol, 122, 130, 10.1046/j.0022-202X.2003.22111.x
Mudaliar, 2003, Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications, Endocr Pract, 9, 406, 10.4158/EP.9.5.406
Delea, 2003, Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study, Diabetes Care, 26, 2983, 10.2337/diacare.26.11.2983
Nesto, 2003, Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E
Chan, 1999, Metformin-associated lactic acidosis: a rare or very rare clinical entity?, Diabetic Med, 16, 273, 10.1046/j.1464-5491.1999.00006.x
Krentz, 2003, Textbook of Diabetes, 32.1